China races to develop brain-computer interfaces that can be inserted in 10 minutes
Chinese start-ups and researchers are accelerating efforts to develop minimally invasive brain-computer interfaces (BCIs) that can be implanted in minutes, aiming to compete with global leaders like Neuralink.
Intelligence analysis by Gemini 2.5 Flash
China is pushing to establish domestic leadership in brain-computer interface technology, with companies like StairMed Technology developing devices that can be inserted via blood vessels, bypassing traditional brain surgery. This rapid development is backed by significant investment and aims to capture a share of the rapidly growing BCI market.
Imagine tiny wires that can let you control a computer with just your thoughts, like magic! Instead of needing a big operation on your head, scientists in China are trying to make these wires so small they can slide into your brain through a blood vessel in your neck, just like putting a tiny tube into your arm. It could take only 10 minutes, making it much easier and safer for people who need help controlling things with their minds.
Analysis
StairMed Technology
Shanghai-based StairMed Technology is at the forefront of China's push into minimally invasive brain-computer interfaces. The company has pioneered a method where BCI devices can be delivered through blood vessels in the neck, guided directly into the brain, and anchored outside the vessel wall. This approach significantly reduces the invasiveness compared to conventional BCIs that necessitate open-brain surgery.
StairMed has garnered substantial financial backing, raising over 1.1 billion yuan (US$163 million) in the past year. Notable investors include Chinese tech giants Tencent Holdings and Alibaba Group Holding, underscoring the strategic importance placed on this technology within China's innovation landscape. The firm's co-founder, Zhao Zhengtuo, highlighted this innovative delivery method at the Global Health Summit in Hong Kong.
2035
The global market for BCI implants is projected for significant expansion, with a Morgan Stanley report estimating its value to reach US$80 billion in the United States alone by 2035. This forecast underscores the immense potential and anticipated demand for such neurotechnologies in the coming decade. China's government has explicitly stated its ambition to cultivate "two or three" globally competitive players in the BCI sector by 2030, signaling a concerted national effort to capture a substantial share of this burgeoning market.
This aggressive timeline and market projection highlight the strategic importance China places on becoming a leader in advanced medical technology and artificial intelligence. The focus on rapid, minimally invasive insertion methods, such as those being developed by StairMed, is key to achieving widespread adoption and market dominance within this timeframe. The ability to implant a device in as little as 10 minutes by an experienced surgeon, as noted by Duan Wanru of Xuanwu Hospital, could be a significant differentiator.
Chinese Academy of Sciences
StairMed Technology's groundbreaking program to insert BCIs via blood vessels is a collaborative effort with a research team from the Chinese Academy of Sciences. This partnership combines the innovative drive of a startup with the deep scientific expertise of a national research institution, accelerating the development and validation of the new technology. Such collaborations are crucial for translating advanced research into practical, deployable medical solutions.
Currently, the technique has undergone testing on sheep, demonstrating its feasibility in animal models. While these initial results are promising, the next critical phase involves commencing human trials. The success of these trials will be pivotal in determining the safety, efficacy, and ultimate viability of this minimally invasive BCI technology for widespread clinical application, marking a significant step towards commercialization and patient benefit.
Key points
- Chinese start-ups are developing brain-computer interfaces (BCIs) that can be implanted in minutes via blood vessels.
- This minimally invasive method avoids traditional brain surgery, making the procedure faster and potentially safer.
- StairMed Technology, a Shanghai-based firm, has raised over US$163 million and is collaborating with the Chinese Academy of Sciences.
- The BCI implant market is projected to reach US$80 billion in the US alone by 2035, with China aiming for global leadership by 2030.
- The technology has been tested on sheep, with human trials yet to begin.
The development of minimally invasive BCIs could significantly improve the quality of life for patients with neurological conditions, offering a faster, safer, and more accessible way to control digital devices with their thoughts. This innovation could also accelerate the broader adoption of BCI technology, leading to new applications in various fields.
Despite promising animal trials, the technology still faces the significant hurdle of successful human trials, which are complex and carry inherent risks. Intense global competition, particularly from established players like Neuralink, also poses a challenge for Chinese firms aiming for market leadership.
